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Background: Endothelial cell (EC) dysfunction is characterized by reduced nitric oxide (NO) bioavailability and is causally associated with 
atherosclerosis. In diabetes, this progressive yet dynamic process may be reversed with a dipeptidyl peptidase-4 (DPP4) inhibitor through enhanced 
glycemic control and incretin activity. In this study, we tested the effects of a DPP4 inhibitor, saxagliptin, on aortic and renal EC function in obese, 
insulin-resistant Zucker rats.
Methods: Obese (fa/fa), insulin-resistant Zucker rats were maintained on a high-fat diet and treated with either vehicle or 10 mg/kg/day 
saxagliptin for 4 or 8 weeks and compared to lean (Fa/fa) rats. Following treatment, NO and peroxynitrite (ONOO-) release kinetics were directly 
measured ex vivo in aortic and glomerular ECs using amperometric approaches. Changes in EC function were correlated with metabolic parameters.
Results: Fasting glucose levels were significantly elevated in obese animals (136 ± 9 mg/dL) as compared to controls (116 ± 4 mg/dL) following 
8 weeks exposure to a high-fat diet. Under these conditions, NO release from aortic and glomerular ECs was reduced by 22% and 31%, respectively, 
in obese versus lean animals; ONOO- release was increased by 26% and 40%, respectively. Saxagliptin treatment reduced blood glucose to levels 
observed in control animals (115 ± 6 mg/dL) and normalized the response to a glucose challenge. Saxagliptin also enhanced aortic and glomerular 
EC function as evidenced by an 18% and 31% increase in NO release, respectively, and comparable reductions in ONOO- levels. Saxagliptin 
increased the NO/ONOO- ratio, an indicator of NO synthase (eNOS) coupling efficiency, by 40% and 64% in aortic and glomerular ECs, respectively. 
The EC benefits of DPP4 inhibition were time-dependent and were observed before reductions in fasting blood glucose levels.
Conclusions: Endothelial function and NO bioavailability were significantly reduced in obese, insulin-resistant rats. Saxagliptin treatment reversed 
these effects by improving NO synthase activity in both aortic and glomerular endothelium before reductions in glucose levels.
